ABSTRACT
Pharmacogenomics, ie, the study of how an individual’s genomic profile influences his or her response to drugs, has emerged as a clinical tool to optimize drug therapy. Certain variants in some genes increase the risk of severe, life-threatening adverse effects from certain drugs. Integrating pharmacogenomics into clinical practice to assist in drug selection and dosing has the potential to improve the outcomes of treatment, reduce the risk of drug-induced morbidity and death, and be cost-effective.
Footnotes
Dr. Hicks has disclosed membership on advisory committee or review panels for 23andMe, research or independent contracting for OneOme, and consulting for Quest Diagnostics.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
- Jennifer K. Hockings, PharmD, PhD⇑
- Department of Pharmacy, Cleveland Clinic; Genomic Medicine Institute, Lerner Research Institute, and Center for Personalized Genetic Healthcare, Cleveland Clinic Community Care
- Address: Jennifer Hockings, PharmD, PhD, Department of Pharmacy, JJN1, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; hockinc{at}ccf.org
- Amy L. Pasternak, PharmD
- Angelika L. Erwin, MD, PhD
- Neil T. Mason, MBA
- Charis Eng, MD, PhD
- J. Kevin Hicks, PharmD, PhD
ABSTRACT
Pharmacogenomics, ie, the study of how an individual’s genomic profile influences his or her response to drugs, has emerged as a clinical tool to optimize drug therapy. Certain variants in some genes increase the risk of severe, life-threatening adverse effects from certain drugs. Integrating pharmacogenomics into clinical practice to assist in drug selection and dosing has the potential to improve the outcomes of treatment, reduce the risk of drug-induced morbidity and death, and be cost-effective.
Footnotes
Dr. Hicks has disclosed membership on advisory committee or review panels for 23andMe, research or independent contracting for OneOme, and consulting for Quest Diagnostics.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.